Compugen’s CGEN-25017, a novel peptide antagonist of the Angiopoietin/Tie-2 pathway, has shown positive therapeutic effects in an animal model of retinopathy. CGEN-25017 had previously demonstrated significant inhibitory activity
Avidas and LaRon have entered into an agreement, where LaRon will co-promote Avidas’ Avidoxy defence kit and Scalacort defence kit . The Avidoxy defence kit includes Avidoxy, indicated
Archemix and Dicerna have entered into an agreement to develop aptamer-DsiRNA therapeutics. Both the firms will work collaboratively on the R&D activities. The agreement includes an option for
In the second quarter of 2009, Lilly reported a worldwide total revenue of $5292.8m, an increase of 3% compared with $5,150.4m for the second quarter of 2008. Net
Gilead has posted a total revenue of $1.65 billion for the second quarter of 2009, an increase of 29% compared to total revenues of $1.28 billion for the
The Society of Chemical Manufacturers and Affiliates (SOCMA) has submitted comments for a hearing of the House Ways and Means Committee. The topic for hearing was on the
Stem Cell Therapeutics (SCT) has received a No Objection Letter (NOL) from the Drug Controller General of India (DCGI), to initiate the phase IIb acute ischemic stroke trial.
Debiopharm has received marketing authorisation for Moapar 11.25mg, from Swissmedic. Moapar 11.25mg is intended for a reversible reduction of serum testosterone to the level of castration in adult
Spectrum Pharmaceuticals and Allergan have announced that the FDA has granted Fast Track Designation (FTD) for the investigation of apaziquone (EOquin. It is developed for the treatment of
Sucampo and Takeda have reported top-line results from two identically-designed phase 3 clinical trials of lubiprostone (24 mcg, twice daily). The drug is for the management of opioid-induced
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.